StockMacro
Menu

Veracyte

$25.13 -43% in 6 monthsMarket cap $2.0B

VCYT on XNAS, Health Care, Veracyte, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 46% in one month despite revenue up 17% to $581.8M over 12 months.

  • BadShort interest at 12% of shares, 8.2 days to cover

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Industry
Services-medical laboratories (Health Care)
Employees
755
Website
veracyte.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $151.8M, net income $31.5M.
Quarter to 31 Dec 2021: revenue $67.3M, net income -$10.5MQuarter to 31 Dec 2021: revenue $67.3M, net income -$10.5MQuarter to 31 Mar 2022: revenue $67.8M, net income -$14.5MQuarter to 31 Mar 2022: revenue $67.8M, net income -$14.5MQuarter to 30 Jun 2022: revenue $72.9M, net income -$9.5MQuarter to 30 Jun 2022: revenue $72.9M, net income -$9.5MQuarter to 30 Sep 2022: revenue $75.6M, net income -$8.7MQuarter to 30 Sep 2022: revenue $75.6M, net income -$8.7MQuarter to 31 Dec 2022: revenue $80.3M, net income -$3.8MQuarter to 31 Dec 2022: revenue $80.3M, net income -$3.8MQuarter to 31 Mar 2023: revenue $82.4M, net income -$8.1MQuarter to 31 Mar 2023: revenue $82.4M, net income -$8.1MQuarter to 30 Jun 2023: revenue $90.3M, net income -$8.4MQuarter to 30 Jun 2023: revenue $90.3M, net income -$8.4MQuarter to 30 Sep 2023: revenue $90.1M, net income -$29.6MQuarter to 30 Sep 2023: revenue $90.1M, net income -$29.6MQuarter to 31 Dec 2023: revenue $98.2M, net income -$28.3MQuarter to 31 Dec 2023: revenue $98.2M, net income -$28.3MQuarter to 31 Mar 2024: revenue $96.8M, net income -$1.9MQuarter to 31 Mar 2024: revenue $96.8M, net income -$1.9MQuarter to 30 Jun 2024: revenue $114.4M, net income $5.7MQuarter to 30 Jun 2024: revenue $114.4M, net income $5.7MQuarter to 30 Sep 2024: revenue $115.9M, net income $15.2MQuarter to 30 Sep 2024: revenue $115.9M, net income $15.2MQuarter to 31 Dec 2024: revenue $118.6M, net income $5.1MQuarter to 31 Dec 2024: revenue $118.6M, net income $5.1MQuarter to 31 Mar 2025: revenue $114.5M, net income $7.0MQuarter to 31 Mar 2025: revenue $114.5M, net income $7.0MQuarter to 30 Jun 2025: revenue $130.2M, net income -$980KQuarter to 30 Jun 2025: revenue $130.2M, net income -$980KQuarter to 30 Sep 2025: revenue $131.9M, net income $19.1MQuarter to 30 Sep 2025: revenue $131.9M, net income $19.1MQuarter to 31 Dec 2025: revenue $140.6M, net income $41.1MQuarter to 31 Dec 2025: revenue $140.6M, net income $41.1MQuarter to 31 Mar 2026: revenue $139.1M, net income $28.7MQuarter to 31 Mar 2026: revenue $139.1M, net income $28.7MQuarter to 30 Jun 2026: revenue $150.3M, net income $25.5MQuarter to 30 Jun 2026: revenue $150.3M, net income $25.5MQuarter to 30 Sep 2026: revenue $151.8M, net income $31.5MQuarter to 30 Sep 2026: revenue $151.8M, net income $31.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $151.8M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$151.8M$31.5M
30 Jun 2026$150.3M$25.5M
31 Mar 2026$139.1M$28.7M
31 Dec 2025$140.6M$41.1M
30 Sep 2025$131.9M$19.1M
30 Jun 2025$130.2M-$980K
31 Mar 2025$114.5M$7.0M
31 Dec 2024$118.6M$5.1M
30 Sep 2024$115.9M$15.2M
30 Jun 2024$114.4M$5.7M
31 Mar 2024$96.8M-$1.9M
31 Dec 2023$98.2M-$28.3M
30 Sep 2023$90.1M-$29.6M
30 Jun 2023$90.3M-$8.4M
31 Mar 2023$82.4M-$8.1M
31 Dec 2022$80.3M-$3.8M
30 Sep 2022$75.6M-$8.7M
30 Jun 2022$72.9M-$9.5M
31 Mar 2022$67.8M-$14.5M
31 Dec 2021$67.3M-$10.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $581.8M $495.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +17% +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $126.8M $30.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $1.54 $0.38
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 72.0% 68.5% 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 17.1% 5.0% -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 21.8% 6.1% -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 9.4% -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $161.9M $98.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $199.8M $315.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$199.8M (net cash) -$315.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $17.76
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 16.0 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.5 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.1 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.4 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
VeracyteVCYT (this company) $2.0B16.03.5+17%21.8%
FortreaFTRE $1.8Bloss0.67-3.4%-2.6%
CelcuityCELC $2.6Bloss–––
PersonalisPSNL $1.5Bloss19.2+17%-148%
Lumexa ImagingLMRI $1.4B––––
CareDxCDNA $3.7B28.67.4+39%25.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$2.9M

bought $0, sold $2.9M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+4.9%

382 13F filers vs 364

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

94.7M shares held by 13F filers (30 Sep 2026) of 80.7M outstanding (30 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

9.6M shares sold short (30 Oct 2026) of 80.7M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.2

9.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-2.7%

9.8M shares sold short in the report before, 9.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

45%

45% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

24

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+15%

$151.8M vs $131.9M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-16%

$2.3M vs $2.8M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$3.5M

the 12 months before: $1.2M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

5

5 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

1.7×

5 articles in the last 7 days; its usual week has 3.

Price $25.13 on 20 Nov 2026, -38% over 12 months (12-month range $24.00 to $60.49)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $18.6M in the last 12 months (the 12 months before: -$10.3M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 12 published in the last 12 months, +50% on the 12 months before.
Revenue per quarter. Revenue $151.8M in the latest quarter, +15% on a year earlier.
Capital spending per quarter. Capital spending $2.3M in the latest quarter, -16% on a year earlier.
Institutional holders (13F filers). 382 13F filers reported holding it in the latest 13F quarter, +36% on a year earlier.
Federal obligations. Federal obligations: $3.4M published in the last 12 months, +56% on the 12 months before.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
14 Sep 20268-K and other filingsCompleted an acquisition or asset sale
11 Jun 20268-K and other filingsDirector or officer change
16 Mar 20268-K and other filingsDirector or officer change
16 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 62 vs usual 28.50 (2025-09-30); 0.9x the same period a year earlier
30 Sep 2025Sharp changeShort interest spike: short interest spike, 9.1M vs usual 3.4M (2025-09-15); 2.6x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 8.0M vs usual 3.3M (2025-08-29); 2.7x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 8.2M vs usual 3.3M (2025-08-15); 2.6x the same period a year earlier
12 Aug 2025Sharp changeShort interest spike: short interest spike, 9.1M vs usual 3.2M (2025-07-31); 3.1x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 6.1M vs usual 3.1M (2025-07-15); 2.0x the same period a year earlier
1 Jul 2025Sharp changeShort interest spike: short interest spike, 5.9M vs usual 3.1M (2025-06-13); 1.3x the same period a year earlier
18 Jun 20258-K and other filingsDirector or officer change
18 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jun 2025Sharp changeShort interest spike: short interest spike, 5.5M vs usual 3.1M (2025-05-30); 1.2x the same period a year earlier
3 Jun 2025Sharp changeShort interest spike: short interest spike, 5.2M vs usual 3.1M (2025-05-15); 1.2x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 5.6M vs usual 3.1M (2025-04-30); 1.3x the same period a year earlier
29 Apr 2025Sharp changeShort interest spike: short interest spike, 5.1M vs usual 3.1M (2025-04-15); 1.4x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 67 vs usual 28.50 (2024-09-30); 2.9x the same period a year earlier
4 Sep 20248-K and other filingsDirector or officer change
13 Jun 20248-K and other filingsDirector or officer change
13 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Feb 20248-K and other filingsDirector or officer change
13 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Feb 20248-K and other filingsCompleted an acquisition or asset sale
8 Aug 20238-K and other filingsDirector or officer change
9 Jun 20238-K and other filingsDirector or officer change
9 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Apr 2023Lobbying filinglobbying engagement terminated (TODD STRATEGY GROUP)
14 Dec 20228-K and other filingsDirector or officer change
14 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Aug 20228-K and other filingsDirector or officer change
11 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Mar 2022Sharp changeQuarterly revenue change: quarterly revenue change, 67.3M vs usual 32.8M (2021-12-31); 1.9x the same period a year earlier
22 Feb 20228-K and other filingsDirector or officer change
11 Jan 20228-K and other filingsDirector or officer change
11 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$804K published
Month from 1 Mar 2022: -$578K published
Month from 1 Jun 2022: $560K published
Month from 1 Aug 2022: -$3.4M published
Month from 1 Nov 2022: -$207K published
Month from 1 Dec 2022: -$2.4M published
Month from 1 Jan 2023: -$2.5M published
Month from 1 Mar 2023: -$1.5M published
Month from 1 Apr 2023: -$749K published
Month from 1 Jun 2023: -$196K published
Month from 1 Jul 2023: -$2.3M published
Month from 1 Mar 2024: -$244K published
Month from 1 Apr 2024: -$216K published
Month from 1 May 2024: -$32K published
Month from 1 Jun 2024: -$211K published
Month from 1 Jul 2024: -$342K published
Month from 1 Aug 2024: -$1.9M published
Month from 1 Sep 2024: -$345K published
Month from 1 Nov 2024: -$1.9M published
Month from 1 Dec 2024: -$1.6M published
Month from 1 Jan 2025: -$403K published
Month from 1 Feb 2025: -$23K published
Month from 1 Mar 2025: -$2.5M published
Month from 1 Jun 2025: -$321K published
Month from 1 Sep 2025: -$310K published
Month from 1 Oct 2025: -$1.2M published
Month from 1 Nov 2025: -$3.9M published
Month from 1 Dec 2025: -$2.5M published
Month from 1 Mar 2026: -$3.2M published
Month from 1 May 2026: -$1.9M published
Month from 1 Jun 2026: -$8.2M published
Month from 1 Sep 2026: -$1.3M published
Month from 1 Oct 2026: -$1.6M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 2 published
Quarter from 1 Oct 2023: 6 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Jul 2024: 8 published
Quarter from 1 Oct 2024: 4 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Jul 2025: 5 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Jan 2026: 3 published
Quarter from 1 Apr 2026: 2 published
Quarter from 1 Jul 2026: 4 published
Quarter from 1 Oct 2026: 3 published
Revenue per quarter
Quarter ended 31 Dec 2021: $67.3M, +95% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $67.8M, +85% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $72.9M, +32% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $75.6M, +25% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $80.3M, +19% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $82.4M, +22% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $90.3M, +24% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $90.1M, +19% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $98.2M, +22% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $96.8M, +17% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $114.4M, +27% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $115.9M, +29% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $118.6M, +21% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $114.5M, +18% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $130.2M, +14% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $131.9M, +14% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $140.6M, +19% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $139.1M, +21% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $150.3M, +15% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $151.8M, +15% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $841K, -5.3% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $2.5M, +105% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $2.5M, +64% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $1.7M, -5.4% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $1.9M, +123% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $993K, -60% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $3.7M, +46% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $2.8M, +63% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $2.5M, +33% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $2.1M, +115% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $2.8M, -25% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $2.2M, -20% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $4.1M, +66% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $1.8M, -15% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $1.3M, -54% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $2.8M, +25% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $3.8M, -8.7% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $3.0M, +63% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $2.9M, +122% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $2.3M, -16% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 195; public on 14 Feb 2022
31 Mar 2022 report: 193; public on 16 May 2022
30 Jun 2022 report: 182; public on 15 Aug 2022
30 Sep 2022 report: 193; public on 14 Nov 2022
31 Dec 2022 report: 207; public on 14 Feb 2023
31 Mar 2023 report: 217; public on 15 May 2023
30 Jun 2023 report: 214; public on 14 Aug 2023
30 Sep 2023 report: 220; public on 14 Nov 2023
31 Dec 2023 report: 236; public on 14 Feb 2024
31 Mar 2024 report: 232; public on 15 May 2024
30 Jun 2024 report: 228; public on 14 Aug 2024
30 Sep 2024 report: 281; public on 14 Nov 2024
31 Dec 2024 report: 307; public on 14 Feb 2025
31 Mar 2025 report: 274; public on 15 May 2025
30 Jun 2025 report: 266; public on 14 Aug 2025
30 Sep 2025 report: 281; public on 14 Nov 2025
31 Dec 2025 report: 315; public on 17 Feb 2026
31 Mar 2026 report: 330; public on 15 May 2026
30 Jun 2026 report: 364; public on 14 Aug 2026
30 Sep 2026 report: 382; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $12K published
Month from 1 Dec 2021: -$10K published
Month from 1 Jan 2022: $70K published
Month from 1 Feb 2022: -$113K published
Month from 1 Mar 2022: $180K published
Month from 1 Apr 2022: -$28K published
Month from 1 Jun 2022: $33K published
Month from 1 Jul 2022: $59K published
Month from 1 Aug 2022: $67K published
Month from 1 Sep 2022: $62K published
Month from 1 Oct 2022: $78K published
Month from 1 Nov 2022: $17K published
Month from 1 Jan 2023: $42K published
Month from 1 Feb 2023: $363K published
Month from 1 Apr 2023: $222K published
Month from 1 May 2023: $76K published
Month from 1 Jun 2023: $212K published
Month from 1 Jul 2023: -$18K published
Month from 1 Sep 2023: $11K published
Month from 1 Oct 2023: -$54K published
Month from 1 Nov 2023: $168K published
Month from 1 Dec 2023: $165K published
Month from 1 Jan 2024: $252K published
Month from 1 Feb 2024: $23K published
Month from 1 Mar 2024: $92K published
Month from 1 Apr 2024: $407K published
Month from 1 May 2024: -$110K published
Month from 1 Jun 2024: -$26K published
Month from 1 Jul 2024: $112K published
Month from 1 Aug 2024: -$33K published
Month from 1 Sep 2024: -$7K published
Month from 1 Oct 2024: $59K published
Month from 1 Nov 2024: $113K published
Month from 1 Dec 2024: $26K published
Month from 1 Jan 2025: $28K published
Month from 1 Feb 2025: $729K published
Month from 1 Mar 2025: $303K published
Month from 1 Apr 2025: $25K published
Month from 1 May 2025: -$10K published
Month from 1 Jun 2025: $69K published
Month from 1 Jul 2025: -$80K published
Month from 1 Aug 2025: -$31K published
Month from 1 Sep 2025: $163K published
Month from 1 Oct 2025: $514K published
Month from 1 Nov 2025: $434K published
Month from 1 Dec 2025: $203K published
Month from 1 Jan 2026: $1.0M published
Month from 1 Feb 2026: $216K published
Month from 1 Mar 2026: $517K published
Month from 1 Apr 2026: -$42K published
Month from 1 May 2026: $75K published
Month from 1 Jun 2026: $467K published
Month from 1 Jul 2026: -$71K published
Month from 1 Aug 2026: $134K published
Month from 1 Sep 2026: -$82K published
Month from 1 Oct 2026: $382K published
Month from 1 Nov 2026: $557K published
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $30K published
Quarter from 1 Oct 2022: $30K published
Quarter from 1 Jan 2023: $30K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $32.2M (30 Sep 2026), 1.8× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $18.6M in the last 12 months (the 12 months before: -$10.3M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 12 published in the last 12 months, +50% on the 12 months before.
  • Revenue per quarter: Revenue $151.8M in the latest quarter, +15% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 9 sales, $2.9M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
28 Oct 2026Jens HolsteinDirectorSellplanned in advance (10b5-1); after exercising options15,000$48.50$728KForm 4
28 Oct 2026Karin EasthamDirectorSellplanned in advance (10b5-1); after exercising options14,850$50.00$743KForm 4
20 Oct 2026Muna BhanjiDirectorSellplanned in advance (10b5-1)1,864$43.70$81KForm 4
22 Sep 2026John LeiteGlobal Chief Commercial OffSellplanned in advance (10b5-1)4,015$40.00$161KForm 4
16 Sep 2026Jens HolsteinDirectorSellplanned in advance (10b5-1)5,000$40.95$205KForm 4
4 Sep 2026Rebecca ChambersChief Financial OfficerSellplanned in advance (10b5-1)3,652$43.10$157KForm 4
4 Sep 2026Annie McGuireEVP, General CounselSellplanned in advance (10b5-1)3,254$43.09$140KForm 4
4 Sep 2026Phillip G. FebboChief Scientific & Med OfficerSellplanned in advance (10b5-1)13,110$43.05$564KForm 4

382 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 69 opened a position, 53 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.13.9M17.2%$639.4M+401K+3.0%
FMR LLC (Fidelity)6.5M8.07%$299.8M-1.2M-15%
State Street Corp5.5M6.86%$254.7M+835K+18%
Vanguard Portfolio Management LLC4.8M5.99%$222.7M+121K+2.6%
Vanguard Capital Management LLC3.6M4.46%$165.8M+6,414+0.2%
ARK Investment Management LLC3.0M3.67%$136.5M+669K+29%
William Blair Investment Management, LLC2.7M3.36%$124.7M+1.3M+89%
Dimensional Fund Advisors LP2.7M3.33%$123.9M-135K-4.8%
GW&K Investment Management, LLC2.4M2.99%+993K+70%
Artisan Partners Limited Partnership2.3M2.87%$106.4M-3.2M-58%

Company events

All 51 company events

In 12 months: 2 director or officer changes, 1 major agreement, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Sep 2026Signed a major agreement; Completed an acquisition or asset sale8-K
11 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
16 Mar 2026Director or officer change8-K
18 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
4 Sep 2024Director or officer change8-K
13 Jun 2024Director or officer changeSame filing: shareholder vote results8-K
13 Feb 2024Director or officer change8-K
6 Feb 2024Completed an acquisition or asset saleSame filing: sold shares privately8-K

24 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 21%, Finance & accounting 12%, Legal, policy & compliance 12%, Sales & business development 12%.

PostedJobLocation
20 Nov 2026Senior Clinical Reimbursement SpecialistFinance & accountingRemote
17 Nov 2026Business Process Analyst, Healthcare Revenue Cycle ManagementFinance & accountingRemote
13 Nov 2026Bioinformatics Scientist IIResearch & scienceRemote; San Diego, California, United States; South San Francisco, California, United States
13 Nov 2026Sr Genomics Specialist, ConnecticutSales & business developmentRemote
11 Nov 2026Histology Technician IILegal, policy & complianceSan Diego, California, United States
11 Nov 2026Sr Genomics Specialist, Long IslandSales & business developmentRemote
10 Nov 2026Sr. Financial AnalystFinance & accountingSan Diego, California, United States; South San Francisco, California, United States
10 Nov 2026Sr. Scientist, Reagent DevelopmentResearch & scienceSouth San Francisco, California, United States

Reported lobbying spend: $30K in Q4 2022, $30K in Q3 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2022EndedTodd Strategy Groupfor Veracyte, Inc.Diagnostics coverage and reimbursement. H.R.4128 - VALID Act of 2021.Health issuesFiling
1 Jan 2016NewTodd Strategy Groupfor Veracyte, Inc.Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payments for clinical laboratory tests. Medicare Treatment of Outpatient Reimbursement for Laboratory tests. FDA regulation of laboratory developed tests.Medicare/Medicaid, MEDFiling

The 5 newest of 154 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

4 Aug 2020confirmed

Confirmed across sources Filings + Financials and Lobbying

Veracyte (VCYT): lobbying on a new issue, while it reported revenue of $20.7M for the quarter ended 30 Jun 2020, 31% below the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Lobbying: Lobbying on a new issue, became public on 14 Jul 2020
  • Financials: Quarterly revenue change, became public on 4 Aug 2020
2018-06-30: $22.8M2018-09-30: $23.5M2018-12-31: $25.8M2019-03-31: $29.5M2019-06-30: $30.1M2019-09-30: $31.0M2019-12-31: $29.7M2020-03-31: $31.1M2020-06-30: $20.7M
The quarter ended 30 Jun 2020 against the 8 quarters before it. this quarterearliernormal: $29.6M
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 14 Jul 2020

Veracyte lobbying on a new issue.

New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12719736

Financials: Quarterly revenue change became public on 4 Aug 2020

Veracyte reported revenue of $20.7M for the quarter ended 30 Jun 2020, 31% below the same quarter last year.

This period
$20.7M (the quarter ended 30 Jun 2020)
Normal quarter (median of 8 earlier)
$29.6M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
-3.0
Same quarter last year
$30.1M
History used
3,013 days
2018-06-30: $22.8M2018-09-30: $23.5M2018-12-31: $25.8M2019-03-31: $29.5M2019-06-30: $30.1M2019-09-30: $31.0M2019-12-31: $29.7M2020-03-31: $31.1M2020-06-30: $20.7M
the quarter ended 30 Jun 20208 earlier quartersnormal: $29.6M

Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 Jan 2019confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

Veracyte (VCYT): saw 37 13F filers open a new position in the quarter ended 30 Sep 2018, 3.7× the same quarter last year; it also had 2.2M shares sold short in the 31 Dec 2018 report, 3.2× the same report last year; and it reported revenue of $25.8M for the quarter ended 31 Dec 2018, 1.3× the same quarter last year. Three unrelated kinds of activity within 56 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2018
  • Short interest and volume: Short interest spike, became public on 11 Jan 2019
  • Short interest and volume: Short interest spike, became public on 26 Jan 2019
  • Financials: Quarterly revenue change, became public on 26 Feb 2019
2016-09-30: 32016-12-31: 212017-03-31: 192017-06-30: 132017-09-30: 102017-12-31: 72018-03-31: 82018-06-30: 122018-09-30: 37
The quarter ended 30 Sep 2018 against the 8 quarters before it. this quarterearliernormal: 11
See the evidence (4 changes)

Institutional holdings: Many funds opening a new position became public on 14 Nov 2018

Veracyte saw 37 13F filers open a new position in the quarter ended 30 Sep 2018, 3.7× the same quarter last year.

This period
37 (the quarter ended 30 Sep 2018)
Normal quarter (median of 8 earlier)
11
Typical spread (median absolute deviation)
3.5
How far from its usual level
+5.0
Same quarter last year
10
History used
1,734 days
2016-09-30: 32016-12-31: 212017-03-31: 192017-06-30: 132017-09-30: 102017-12-31: 72018-03-31: 82018-06-30: 122018-09-30: 37
the quarter ended 30 Sep 20188 earlier quartersnormal: 11

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Jan 2019

Veracyte had 2.2M shares sold short in the 31 Dec 2018 report, 3.2× the same report last year.

This period
2.2M (the 31 Dec 2018 report)
Normal report (median of 20 earlier)
817K
Typical spread (median absolute deviation)
137K
How far from its usual level
+6.5
Same report last year
668K
History used
367 days
2017-12-29: 668K2018-01-12: 742K2018-01-31: 738K2018-02-15: 728K2018-02-28: 868K2018-03-15: 924K2018-05-15: 811K2018-06-15: 768K2018-06-29: 598K2018-07-13: 585K2018-07-31: 545K2018-08-15: 785K2018-08-31: 823K2018-09-14: 943K2018-09-28: 1.1M2018-10-15: 1.0M2018-10-31: 1.0M2018-11-15: 1.6M2018-11-30: 1.5M2018-12-14: 1.4M2018-12-31: 2.2M
the 31 Dec 2018 report20 earlier reportsnormal: 817K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jan 2019

Veracyte had 1.8M shares sold short in the 15 Jan 2019 report, 2.5× the same report last year.

This period
1.8M (the 15 Jan 2019 report)
Normal report (median of 21 earlier)
823K
Typical spread (median absolute deviation)
154K
How far from its usual level
+4.5
Same report last year
742K
History used
382 days
2017-12-29: 668K2018-01-12: 742K2018-01-31: 738K2018-02-15: 728K2018-02-28: 868K2018-03-15: 924K2018-05-15: 811K2018-06-15: 768K2018-06-29: 598K2018-07-13: 585K2018-07-31: 545K2018-08-15: 785K2018-08-31: 823K2018-09-14: 943K2018-09-28: 1.1M2018-10-15: 1.0M2018-10-31: 1.0M2018-11-15: 1.6M2018-11-30: 1.5M2018-12-14: 1.4M2018-12-31: 2.2M2019-01-15: 1.8M
the 15 Jan 2019 report21 earlier reportsnormal: 823K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 26 Feb 2019

Veracyte reported revenue of $25.8M for the quarter ended 31 Dec 2018, 1.3× the same quarter last year.

This period
$25.8M (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
$19.0M
Typical spread (median absolute deviation)
$1.3M
How far from its usual level
+3.6
Same quarter last year
$19.6M
History used
2,466 days
2016-12-31: $18.3M2017-03-31: $16.4M2017-06-30: $18.4M2017-09-30: $17.5M2017-12-31: $19.6M2018-03-31: $20.0M2018-06-30: $22.8M2018-09-30: $23.5M2018-12-31: $25.8M
the quarter ended 31 Dec 20188 earlier quartersnormal: $19.0M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 14 Sep 2026Filings record

    Completed an acquisition or asset sale

  2. 11 Jun 2026Filings record

    Director or officer change

  3. 16 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 16 Mar 2026Filings record

    Director or officer change

  5. 14 Nov 2025Institutional holdings change

    saw 62 13F filers open a new position in the quarter ended 30 Sep 2025, 7.5% below the same quarter last year.

    Same quarter last year: 67; its normal quarter is 28.5.

    See the evidence
    This period
    62 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    28.5
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +4.5
    Same quarter last year
    67
    History used
    4,291 days
    2023-09-30: 232023-12-31: 242024-03-31: 332024-06-30: 242024-09-30: 672024-12-31: 392025-03-31: 222025-06-30: 332025-09-30: 62
    the quarter ended 30 Sep 20258 earlier quartersnormal: 28.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 25 Sep 2025Short interest and volume change

    had 9.1M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.

    Same report last year: 3.5M; its normal report is 3.4M.

    See the evidence
    This period
    9.1M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    687K
    How far from its usual level
    +5.6
    Same report last year
    3.5M
    History used
    2,817 days
    2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M2025-05-30: 5.5M2025-06-13: 5.9M2025-06-30: 6.2M2025-07-15: 6.1M2025-07-31: 9.1M2025-08-15: 8.2M2025-08-29: 8.0M2025-09-15: 9.1M
    the 15 Sep 2025 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 11 Sep 2025Short interest and volume change

    had 8.0M shares sold short in the 29 Aug 2025 report, 2.7× the same report last year.

    Same report last year: 2.9M; its normal report is 3.3M.

    See the evidence
    This period
    8.0M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    511K
    How far from its usual level
    +6.2
    Same report last year
    2.9M
    History used
    2,800 days
    2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M2025-05-30: 5.5M2025-06-13: 5.9M2025-06-30: 6.2M2025-07-15: 6.1M2025-07-31: 9.1M2025-08-15: 8.2M2025-08-29: 8.0M
    the 29 Aug 2025 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 27 Aug 2025Short interest and volume change

    had 8.2M shares sold short in the 15 Aug 2025 report, 2.6× the same report last year.

    Same report last year: 3.1M; its normal report is 3.3M.

    See the evidence
    This period
    8.2M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    380K
    How far from its usual level
    +8.6
    Same report last year
    3.1M
    History used
    2,786 days
    2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M2025-05-30: 5.5M2025-06-13: 5.9M2025-06-30: 6.2M2025-07-15: 6.1M2025-07-31: 9.1M2025-08-15: 8.2M
    the 15 Aug 2025 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 12 Aug 2025Short interest and volume change

    had 9.1M shares sold short in the 31 Jul 2025 report, 3.1× the same report last year.

    Same report last year: 3.0M; its normal report is 3.2M.

    See the evidence
    This period
    9.1M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    284K
    How far from its usual level
    +13.9
    Same report last year
    3.0M
    History used
    2,771 days
    2024-07-31: 3.0M2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M2025-05-30: 5.5M2025-06-13: 5.9M2025-06-30: 6.2M2025-07-15: 6.1M2025-07-31: 9.1M
    the 31 Jul 2025 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 25 Jul 2025Short interest and volume change

    had 6.1M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.

    Same report last year: 3.1M; its normal report is 3.1M.

    See the evidence
    This period
    6.1M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    230K
    How far from its usual level
    +8.7
    Same report last year
    3.1M
    History used
    2,755 days
    2024-07-15: 3.1M2024-07-31: 3.0M2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M2025-05-30: 5.5M2025-06-13: 5.9M2025-06-30: 6.2M2025-07-15: 6.1M
    the 15 Jul 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 26 Jun 2025Short interest and volume change

    had 5.9M shares sold short in the 13 Jun 2025 report, 1.3× the same report last year.

    Same report last year: 4.5M; its normal report is 3.1M.

    See the evidence
    This period
    5.9M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    206K
    How far from its usual level
    +9.0
    Same report last year
    4.5M
    History used
    2,723 days
    2024-06-14: 4.5M2024-06-28: 2.9M2024-07-15: 3.1M2024-07-31: 3.0M2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M2025-05-30: 5.5M2025-06-13: 5.9M
    the 13 Jun 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 18 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 18 Jun 2025Filings record

    Director or officer change

  14. 11 Jun 2025Short interest and volume change

    had 5.5M shares sold short in the 30 May 2025 report, 1.2× the same report last year.

    Same report last year: 4.4M; its normal report is 3.1M.

    See the evidence
    This period
    5.5M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    206K
    How far from its usual level
    +7.5
    Same report last year
    4.4M
    History used
    2,709 days
    2024-05-31: 4.4M2024-06-14: 4.5M2024-06-28: 2.9M2024-07-15: 3.1M2024-07-31: 3.0M2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M2025-05-30: 5.5M
    the 30 May 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 28 May 2025Short interest and volume change

    had 5.2M shares sold short in the 15 May 2025 report, 1.2× the same report last year.

    Same report last year: 4.5M; its normal report is 3.1M.

    See the evidence
    This period
    5.2M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    206K
    How far from its usual level
    +6.7
    Same report last year
    4.5M
    History used
    2,694 days
    2024-05-15: 4.5M2024-05-31: 4.4M2024-06-14: 4.5M2024-06-28: 2.9M2024-07-15: 3.1M2024-07-31: 3.0M2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M2025-05-15: 5.2M
    the 15 May 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 10 May 2025Short interest and volume change

    had 5.6M shares sold short in the 30 Apr 2025 report, 1.3× the same report last year.

    Same report last year: 4.4M; its normal report is 3.1M.

    See the evidence
    This period
    5.6M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    206K
    How far from its usual level
    +7.8
    Same report last year
    4.4M
    History used
    2,679 days
    2024-04-30: 4.4M2024-05-15: 4.5M2024-05-31: 4.4M2024-06-14: 4.5M2024-06-28: 2.9M2024-07-15: 3.1M2024-07-31: 3.0M2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M2025-04-30: 5.6M
    the 30 Apr 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 26 Apr 2025Short interest and volume change

    had 5.1M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.

    Same report last year: 3.6M; its normal report is 3.1M.

    See the evidence
    This period
    5.1M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    3.1M
    Typical spread (median absolute deviation)
    206K
    How far from its usual level
    +6.4
    Same report last year
    3.6M
    History used
    2,664 days
    2024-04-15: 3.6M2024-04-30: 4.4M2024-05-15: 4.5M2024-05-31: 4.4M2024-06-14: 4.5M2024-06-28: 2.9M2024-07-15: 3.1M2024-07-31: 3.0M2024-08-15: 3.1M2024-08-30: 2.9M2024-09-13: 3.5M2024-09-30: 3.3M2024-10-15: 3.1M2024-10-31: 3.1M2024-11-15: 2.9M2024-11-29: 3.0M2024-12-13: 2.5M2024-12-31: 2.8M2025-01-15: 3.0M2025-01-31: 3.2M2025-02-14: 3.1M2025-02-28: 3.4M2025-03-14: 3.3M2025-03-31: 4.2M2025-04-15: 5.1M
    the 15 Apr 2025 report24 earlier reportsnormal: 3.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 14 Nov 2024Institutional holdings change

    saw 67 13F filers open a new position in the quarter ended 30 Sep 2024, 2.9× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 28.5.

    See the evidence
    This period
    67 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    28.5
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +5.2
    Same quarter last year
    23
    History used
    3,926 days
    2022-09-30: 342022-12-31: 382023-03-31: 332023-06-30: 192023-09-30: 232023-12-31: 242024-03-31: 332024-06-30: 242024-09-30: 67
    the quarter ended 30 Sep 20248 earlier quartersnormal: 28.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  19. 4 Sep 2024Filings record

    Director or officer change

  20. 13 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 13 Jun 2024Filings record

    Director or officer change

  22. 13 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 13 Feb 2024Filings record

    Director or officer change

  24. 6 Feb 2024Filings record

    Completed an acquisition or asset sale

  25. 8 Aug 2023Filings record

    Director or officer change

  26. 9 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 9 Jun 2023Filings record

    Director or officer change

  28. 20 Apr 2023Lobbying record

    VERACYTE, INC.: lobbying engagement terminated (TODD STRATEGY GROUP) (dated 31 Dec 2022)

  29. 14 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 14 Dec 2022Filings record

    Director or officer change

  31. 11 Aug 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 11 Aug 2022Filings record

    Director or officer change

  33. 14 Jun 2022Insiders record

    Stapley Marc (Chief Executive Officer) bought 60,000 shares of VCYT ($979,800) (dated 13 Jun 2022)

  34. 1 Mar 2022Financials change

    reported revenue of $67.3M for the quarter ended 31 Dec 2021, 1.9× the same quarter last year.

    Same quarter last year: $34.5M; its normal quarter is $32.8M.

    See the evidence
    This period
    $67.3M (the quarter ended 31 Dec 2021)
    Normal quarter (median of 8 earlier)
    $32.8M
    Typical spread (median absolute deviation)
    $3.5M
    How far from its usual level
    +6.7
    Same quarter last year
    $34.5M
    History used
    3,562 days
    2019-12-31: $29.7M2020-03-31: $31.1M2020-06-30: $20.7M2020-09-30: $31.1M2020-12-31: $34.5M2021-03-31: $36.7M2021-06-30: $55.1M2021-09-30: $60.4M2021-12-31: $67.3M
    the quarter ended 31 Dec 20218 earlier quartersnormal: $32.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 22 Feb 2022Filings record

    Director or officer change

  36. 11 Jan 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 11 Jan 2022Filings record

    Director or officer change

  38. 16 Nov 2021Financials change

    reported revenue of $60.4M for the quarter ended 30 Sep 2021, 1.9× the same quarter last year.

    Same quarter last year: $31.1M; its normal quarter is $31.1M.

    See the evidence
    This period
    $60.4M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    $31.1M
    Typical spread (median absolute deviation)
    $2.4M
    How far from its usual level
    +8.2
    Same quarter last year
    $31.1M
    History used
    3,470 days
    2019-09-30: $31.0M2019-12-31: $29.7M2020-03-31: $31.1M2020-06-30: $20.7M2020-09-30: $31.1M2020-12-31: $34.5M2021-03-31: $36.7M2021-06-30: $55.1M2021-09-30: $60.4M
    the quarter ended 30 Sep 20218 earlier quartersnormal: $31.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  39. 3 Aug 2021Financials change

    reported revenue of $55.1M for the quarter ended 30 Jun 2021, 2.7× the same quarter last year.

    Same quarter last year: $20.7M; its normal quarter is $31.0M.

    See the evidence
    This period
    $55.1M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $31.0M
    Typical spread (median absolute deviation)
    $1.1M
    How far from its usual level
    +7.7
    Same quarter last year
    $20.7M
    History used
    3,378 days
    2019-06-30: $30.1M2019-09-30: $31.0M2019-12-31: $29.7M2020-03-31: $31.1M2020-06-30: $20.7M2020-09-30: $31.1M2020-12-31: $34.5M2021-03-31: $36.7M2021-06-30: $55.1M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $31.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  40. 3 Aug 2021Filings record

    Completed an acquisition or asset sale

Showing the newest 40 of 84 entries; narrow the window or the kind of data to see older ones.

Not listed: 331 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001384101
Ticker
VCYT
Domain
veracyte.com
Employer name
Veracyte, Inc. (1 unverified)
Hq location
CA|SOUTH SAN FRANCISCO|94080 (1 unverified)
Lobbying client
veracyte
Name
C2i Genomics Ltd, CALDEROME INC, Legal Entity Name, Veracyte Diagnostics, LLC and 6 more
Uei
DKKCNLTYT2A1, JS7GBP6LCMN6
  • DOL H-1B labor condition applications and PERM certifications245 data points2 Dec 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)2 records, 84 data points1 Jan 2016 to 31 Dec 2022
  • SEC Form 13F institutional holdings468 data points31 Dec 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)162 records4 Mar 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)984 data points31 Dec 2010 to 30 Oct 2026
  • SEC Form 4 insider transactions213 records, 652 data points1 Jun 2016 to 28 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards864 data points23 Oct 2012 to 20 Nov 2026